Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254904 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
NCT00254904 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 839 participants.
The verdict
NCT00254904, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of PF-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of gemcitabine/cisplatin alone.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Gemcitabine + Cisplatin
- DRUG PF-3512676
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254904
The ClinicalTrials.gov registry entry for NCT00254904 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 839 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00254904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254904 about?
NCT00254904 is a clinical study titled "Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC". To assess the efficacy and safety of PF-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of gemcitabine/cisplatin alone.
What is the current status of trial NCT00254904?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2005-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00254904?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Gemcitabine + Cisplatin (DRUG), PF-3512676 (DRUG).
Who is sponsoring clinical trial NCT00254904?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.